FAM117B Promotes Gastric Cancer Growth and Drug Resistance by Targeting the KEAP1/NRF2 Signaling Pathway

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2023 Jan 31

PMID 36719368

Authors

Yunjiang Zhou

Yaxin Chen

Yongwei Shi

Leyin Wu

Yingying Tan

Tao Li

Yigang Chen

Jiazeng Xia

Rong Hu

Affiliations

Soon will be listed here.

Abstract

Gastric cancer often shows malignant growth and insensitivity to chemotherapeutic drugs due to the regulation of complex molecular mechanisms, which results in poor prognosis for patients. However, the relevant molecular mechanisms remain unclear. In this study, we reported that family with sequence similarity 117, member B (FAM117B), promoted the growth of gastric cancer cells and reduced the sensitivity of cells to chemotherapeutic drugs. Mechanistically, FAM117B competed with nuclear factor E2-related factor 2 (NRF2) for Kelch-like ECH-associated protein 1 (KEAP1) binding, reduced the ubiquitination degradation of NRF2, and activated the KEAP1/NRF2 signaling pathway. Moreover, FAM117B-induced growth and chemoresistance of gastric cancer cells were NRF2 dependent. We found that FAM117B and NRF2 protein levels were highly expressed in tumor tissues of patients with gastric cancer and their co-overexpression represented an independent factor for poor prognosis. Collectively, our findings reveal that FAM117B is involved in promoting gastric cancer growth and drug resistance, and it could be exploited as a cancer therapeutic target.

Citing Articles

Reversal of chemotherapy resistance in gastric cancer with traditional Chinese medicine as sensitizer: potential mechanism of action.

Zhou C, Wu K, Gu M, Yang Y, Tu J, Huang X Front Oncol. 2025; 15:1524182.

PMID: 40052129 PMC: 11882405. DOI: 10.3389/fonc.2025.1524182.

KEAP1-NRF2 Interaction in Cancer: Competitive Interactors and Their Role in Carcinogenesis.

Oskomic M, Tomic A, Barbaric L, Matic A, Kindl D, Matovina M Cancers (Basel). 2025; 17(3).

PMID: 39941813 PMC: 11816071. DOI: 10.3390/cancers17030447.

The Crosstalk between Autophagy and Nrf2 Signaling in Cancer: from Biology to Clinical Applications.

Shan C, Wang Y, Wang Y Int J Biol Sci. 2024; 20(15):6181-6206.

PMID: 39664581 PMC: 11628323. DOI: 10.7150/ijbs.103187.

CRL3 E3 ligase facilitates ubiquitin-mediated degradation of oncogenic SRX to suppress colorectal cancer progression.

Zhu F, Li L, Chen Y, Pan Y, Zhang W, Li L Nat Commun. 2024; 15(1):10536.

PMID: 39627198 PMC: 11615322. DOI: 10.1038/s41467-024-54919-2.

NRF2 signaling plays an essential role in cancer progression through the NRF2-GPX2-NOTCH3 axis in head and neck squamous cell carcinoma.

Jin X, Lou X, Qi H, Zheng C, Li B, Siwu X Oncogenesis. 2024; 13(1):35.

PMID: 39333079 PMC: 11437035. DOI: 10.1038/s41389-024-00536-z.

References

Zhang D, Hannink M . Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress. Mol Cell Biol. 2003; 23(22):8137-51. PMC: 262403. DOI: 10.1128/MCB.23.22.8137-8151.2003. View

Best S, Ding S, Kersbergen A, Dong X, Song J, Xie Y . Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nat Commun. 2019; 10(1):4190. PMC: 6744438. DOI: 10.1038/s41467-019-12164-y. View

Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y . The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. 2010; 12(3):213-23. DOI: 10.1038/ncb2021. View

Takahashi T, Sonobe M, Menju T, Nakayama E, Mino N, Iwakiri S . Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. J Surg Oncol. 2010; 101(6):500-6. DOI: 10.1002/jso.21520. View

Zhou Y, Zhou Y, Wang K, Li T, Yang M, Wang R . Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway. Cancer Lett. 2020; 474:94-105. DOI: 10.1016/j.canlet.2020.01.010. View

Fan Z, Wirth A, Chen D, Wruck C, Rauh M, Buchfelder M . Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis. Oncogenesis. 2017; 6(8):e371. PMC: 5608917. DOI: 10.1038/oncsis.2017.65. View

Wang Q, Ma J, Lu Y, Zhang S, Huang J, Bei J . CDK20 interacts with KEAP1 to activate NRF2 and promotes radiochemoresistance in lung cancer cells. Oncogene. 2017; 36(37):5321-5330. DOI: 10.1038/onc.2017.161. View

Mukhopadhyay S, Goswami D, Adiseshaiah P, Burgan W, Yi M, Guerin T . Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers. Cancer Res. 2020; 80(8):1630-1643. PMC: 7185043. DOI: 10.1158/0008-5472.CAN-19-1363. View

Zhang B, Wu J, Cai Y, Luo M, Wang B, Gu Y . TCF7L1 indicates prognosis and promotes proliferation through activation of Keap1/NRF2 in gastric cancer. Acta Biochim Biophys Sin (Shanghai). 2019; 51(4):375-385. PMC: 6460344. DOI: 10.1093/abbs/gmz015. View

10.

Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N . Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 2009; 15(10):3423-32. DOI: 10.1158/1078-0432.CCR-08-2822. View

11.

Magesh S, Chen Y, Hu L . Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med Res Rev. 2012; 32(4):687-726. PMC: 3393814. DOI: 10.1002/med.21257. View

12.

Gambardella V, Gimeno-Valiente F, Tarazona N, Martinez-Ciarpaglini C, Roda D, Fleitas T . NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in -Amplified Gastric Cancer. Clin Cancer Res. 2018; 25(5):1639-1649. DOI: 10.1158/1078-0432.CCR-18-2421. View

13.

Traylor M, Persyn E, Tomppo L, Klasson S, Abedi V, Bakker M . Genetic basis of lacunar stroke: a pooled analysis of individual patient data and genome-wide association studies. Lancet Neurol. 2021; 20(5):351-361. PMC: 8062914. DOI: 10.1016/S1474-4422(21)00031-4. View

14.

Ge W, Zhao K, Wang X, Li H, Yu M, He M . iASPP Is an Antioxidative Factor and Drives Cancer Growth and Drug Resistance by Competing with Nrf2 for Keap1 Binding. Cancer Cell. 2017; 32(5):561-573.e6. DOI: 10.1016/j.ccell.2017.09.008. View

15.

Tsuchida K, Tsujita T, Hayashi M, Ojima A, Keleku-Lukwete N, Katsuoka F . Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med. 2017; 103:236-247. DOI: 10.1016/j.freeradbiomed.2016.12.041. View

16.

Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A . PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol. 2012; 32(8):1506-17. PMC: 3318596. DOI: 10.1128/MCB.06271-11. View

17.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

18.

Ren D, Villeneuve N, Jiang T, Wu T, Lau A, Toppin H . Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A. 2011; 108(4):1433-8. PMC: 3029730. DOI: 10.1073/pnas.1014275108. View

19.

DeNicola G, Karreth F, Humpton T, Gopinathan A, Wei C, Frese K . Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011; 475(7354):106-9. PMC: 3404470. DOI: 10.1038/nature10189. View

20.

Zhang Q, Zhang Z, Du H, Li S, Tu R, Jia Y . DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. Cell Death Differ. 2019; 26(11):2300-2313. PMC: 6889501. DOI: 10.1038/s41418-019-0303-z. View